Clinical trials - Press Releases

Date	Title	Company
06-May-2021	Parexel Achieves Top Rankings in Industry Across Multiple Attributes in ISR CRO Phase II-III Benchmarking Report	Parexel
05-May-2021	TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital open cancer immunotherapy clinical trial	TILT Biotherapeutics
05-May-2021	CMED GROUP joins AIXIAL GROUP, the CRO of ALTEN GROUP	Scott PR
05-May-2021	Parexel Achieves Top Rankings in Industry Across Multiple Attributes in ISR CRO Phase II-III Benchmarking Report	Parexel
04-May-2021	THREAD and Trialbee Partner to Enhance Global Decentralized Clinical Trial Inclusivity and Recruitment Outcomes	Trialbee
04-May-2021	Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes	Farxiga
04-May-2021	Pharmaceutical Intermediate Market projected to reach US$ 37,290.33 million by 2028 \| Codexis, chiracon, Vertellus Holdings, Lianhe Chemical Technology,	theinsightpartners
04-May-2021	Medical Cannabis Market Hits US$ 49,116.4 million by 2028 and to grow at a CAGR of 23.9% - Aphria, Aurora Cannabis, VIVO Cannabis, Tilray, CANVORY	theinsightpartners
01-May-2021	Agilex Biolabs Congratulates Bionomics Limited on BNC210 PK Results	Agilex Biolabs
30-Apr-2021	VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China	Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
29-Apr-2021	Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 Test Used in DIRECT study to Investigate the T Cell Response and COVID vaccination in Ethnic Minority Groups.	Oxford Immunotec
29-Apr-2021	Panthera becomes the world’s first clinical trial site to administer Valneva’s inactivated COVID-19 vaccine (VLA2001) to volunteers in phase 3 study	Panthera
29-Apr-2021	Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)	Pharnext SA
29-Apr-2021	Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury	Vifor Pharma
29-Apr-2021	HUTCHMED Initiates Phase II Registration Study of HMPL 689 in Patients with Follicular Lymphoma and Marginal Zone Lymphoma in China	HUTCHMED
29-Apr-2021	Panthera becomes the world’s first clinical trial site to administer Valneva’s inactivated COVID-19 vaccine (VLA2001) to volunteers in phase 3 study	Panthera
28-Apr-2021	ViroCell, the UK’s first clinical trial focused viral vector manufacturer, announces its official launch	ViroCell
28-Apr-2021	Amgen Provides Updated Information On LUMAKRAS™ (Sotorasib)¹ Dose Comparison Study	Amgen
28-Apr-2021	Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial	Sanofi
28-Apr-2021	ReiThera Completes Enrolment of Subjects in the Phase 2 Part of the Phase 2/3 Clinical Trial of its GRAd-COV2 Vaccine Candidate against COVID-19	ReiThera Srl